Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Catherine Daniel"'
Autor:
Catherine, Daniel, Amélie, Dewitte, Sabine, Poiret, Michaël, Marceau, Michel, Simonet, Laure, Marceau, Guillaume, Descombes, Denise, Boutillier, Nadia, Bennaceur, Sébastien, Bontemps-Gallo, Nadine, Lemaître, Florent, Sebbane
Publikováno v:
Frontiers in Immunology
Yersinioses caused by Yersinia pestis, Yersinia pseudotuberculosis, and Yersinia enterocolitica are significant concerns in human and veterinary health. The link between virulence and the potent LcrV antigen has prompted the latter's selection as a m
Autor:
Lauren E. Strelec, Sunita D. Nasta, Jakub Svoboda, Sarah Brooks, Prioty Islam, Chadi Nabhan, Anthony R. Mato, Catherine Daniel, Alex Ganetsky, David L. Porter, Stephen J. Schuster, Adam H. Kaye
Publikováno v:
Blood. 127:1064-1067
To the editor: Chronic lymphocytic leukemia (CLL) is a B-cell lymphoproliferative disorder partly dependent on the B-cell receptor (BCR) signaling pathway. The novel BCR signal transduction inhibitor ibrutinib has emerged as an effective therapeutic
Autor:
Bruno Pot, Catherine Daniel, Paul de Vos, Miriam Bermudez-Brito, Theo Borghuis, Bart J. de Haan, Marijke M. Faas
Publikováno v:
Scientific Reports
Scientific Reports, Nature Publishing Group, 2018, 8 (1), pp.1785. ⟨10.1038/s41598-018-20243-1⟩
Scientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
Scientific Reports, 2018, 8 (1), pp.1785. ⟨10.1038/s41598-018-20243-1⟩
Scientific Reports, 8(1):1785. Nature Publishing Group
Scientific Reports, Nature Publishing Group, 2018, 8 (1), pp.1785. ⟨10.1038/s41598-018-20243-1⟩
Scientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
Scientific Reports, 2018, 8 (1), pp.1785. ⟨10.1038/s41598-018-20243-1⟩
Scientific Reports, 8(1):1785. Nature Publishing Group
Probiotics such as L. plantarum WCFS1 can modulate immune responses in healthy subjects but how this occurs is still largely unknown. Immune-sampling in the Peyer Patches has been suggested to be one of the mechanisms. Here we studied the systemic an
Autor:
Jérôme Breton, Anne Garat, Mathilde Body-Malapel, Coline Plé, Benoît Foligné, Cécile Vignal, Catherine Daniel
Publikováno v:
Scientific Reports
Scientific Reports, Nature Publishing Group, 2016, Scientific Reports, 6, ⟨10.1038/srep19200⟩
Scientific Reports, Nature Publishing Group, 2016, Scientific Reports, 6 (1), pp.19200. ⟨10.1038/srep19200⟩
Scientific Reports, 2016, Scientific Reports, 6, ⟨10.1038/srep19200⟩
Scientific Reports, Nature Publishing Group, 2016, Scientific Reports, 6, ⟨10.1038/srep19200⟩
Scientific Reports, Nature Publishing Group, 2016, Scientific Reports, 6 (1), pp.19200. ⟨10.1038/srep19200⟩
Scientific Reports, 2016, Scientific Reports, 6, ⟨10.1038/srep19200⟩
Although the heavy metals cadmium (Cd) and lead (Pb) are known environmental health concerns, their long-term impacts on gut ecology and susceptibility to gastrointestinal autoimmune diseases have not been extensively investigated. We sought to deter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51c7cc50d8e154808025df61383bfe2a
https://hal.archives-ouvertes.fr/hal-01935794
https://hal.archives-ouvertes.fr/hal-01935794
Autor:
Martin Schwarzer, Andreas Repa, Bruno Pot, Irma Schabussova, Tomas Hrncir, Ursula Wiedermann, Renata Stepankova, Tomas Hudcovic, Hana Kozakova, Helena Tlaskalova-Hogenova, Catherine Daniel, Arnold Pollak
Publikováno v:
Allergy. 66:368-375
To cite this article: Schwarzer M, Repa A, Daniel C, Schabussova I, Hrncir T, Pot B, Stepankova R, Hudcovic T, Pollak A, Tlaskalova-Hogenova H, Wiedermann U, Kozakova H. Neonatal colonization of mice with Lactobacillus plantarum producing the aeroall
Publikováno v:
Allergy, 62(11), 1237-1242
Allergy 62 (2007) 11
Allergy 62 (2007) 11
In March 2001, the European Commission funded a 3-year project (contract no. QLK3-CT-2000-00340) under the fifth Framework Programme to develop and test prototype products based on the oral delivery of vaccine and therapeutic agents using harmless la
Autor:
Andreas Repa, C. Wild, Heimo Breiteneder, Arnold Pollak, Catherine Daniel, Annick Mercenier, Ursula Wiedermann, Bruno Pot
Publikováno v:
Allergy. 61:812-819
BACKGROUND: Probiotic lactic acid bacteria (LAB) are able to modulate the host immune system and clinical trials have demonstrated that specific strains have the capacity to reduce allergic symptoms. Therefore, we aimed to evaluate the potential of r
Autor:
Bruno Pot, Ghalia Kaci, Hervé M. Blottière, Pierre Renault, Véronique Dennin, Catherine Daniel, Joël Doré, Christine Delorme, S. Dusko Ehrlich, Denise Goudercourt
Publikováno v:
Applied and Environmental Microbiology
Applied and Environmental Microbiology, American Society for Microbiology, 2014, 80 (3), pp.928-934. ⟨10.1128/AEM.03133-13⟩
Applied and Environmental Microbiology, 2014, 80 (3), pp.928-934. ⟨10.1128/AEM.03133-13⟩
Applied and Environmental Microbiology 3 (80), 928-934. (2014)
Applied and Environmental Microbiology, American Society for Microbiology, 2014, 80 (3), pp.928-934. ⟨10.1128/AEM.03133-13⟩
Applied and Environmental Microbiology, 2014, 80 (3), pp.928-934. ⟨10.1128/AEM.03133-13⟩
Applied and Environmental Microbiology 3 (80), 928-934. (2014)
Streptococcus salivarius is one of the first colonizers of the human oral cavity and gut after birth and therefore may contribute to the establishment of immune homeostasis and regulation of host inflammatory responses. The anti-inflammatory potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e08ce185c8bd4692d37148c0ca572dc3
https://hal.archives-ouvertes.fr/hal-01204328
https://hal.archives-ouvertes.fr/hal-01204328
Autor:
Pavel Kiselev, Chaitra S. Ujjani, Melissa Yacur, Molly Fanning, Stephen J. Schuster, Allan-Louie Cruz, Paul M. Barr, Clive S. Zent, Spencer Henick Bachow, Anthony R. Mato, Bruce D. Cheson, Nicole Lamanna, Brian T. Hill, Alan P Skarbnik, Jeffrey J. Pu, Catherine Daniel, Danielle M. Brander, Christina Howlett, Allison M. Winter, Colleen Timlin, Krista Isaack, David F. Claxton, Jakub Svoboda, Chadi Nabhan, Kaitlin Kennard
Publikováno v:
Blood. 128:4400-4400
Introduction: Ibrutinib (Ibr), idelalisib (Ide), andvenetoclax (Ven), are all now approved for treating CLL patients in the US. However, in the absence of head-to-head comparator trials, there is limited guidance as to the optimal sequence of these t
Autor:
Anthony R. Mato, David F. Claxton, Bruce D. Cheson, Jeffrey J. Pu, Clive S. Zent, Molly Fanning, Colleen Timlin, Lauren E. Strelec, Krista Isaack, Allan-Louie Cruz, Paul M. Barr, Nicole Lamanna, David L. Porter, Catherine Daniel, Daniel J. Landsburg, Spencer Henick Bachow, Chaitra S. Ujjani, Pavel Kiselev, Melissa Yacur, Christina Howlett, Allison M. Winter, Danielle M. Brander, Kaitlin Kennard, Chadi Nabhan, Stephen J. Schuster, Brian T. Hill, Alan P Skarbnik, Sunita D. Nasta
Publikováno v:
Blood. 128:3222-3222
Introduction: Ibrutinib (Ibr) is a kinase inhibitor (KI) indicated for treating CLL. Clinical trials that led to its approval showed that its unique side effects differ from traditional chemotherapy toxicities. We previously reported (Mato et al, ASH